8-K: Bolt Biotherapeutics Announces 1-for-20 Reverse Stock Split to Boost Share Price

Bolt Biotherapeutics, Inc. has announced a 1-for-20 reverse stock split of its common stock, effective June 6, 2025, to consolidate shares and potentially maintain Nasdaq listing compliance.

Summary

• Bolt Biotherapeutics, Inc. (BOLT) will effect a one-for-twenty (1:20) reverse stock split of its outstanding common stock.
• The reverse stock split was approved by the Board of Directors and stockholders on May 27, 2025.
• The Amendment to the Company's Certificate of Incorporation will be effective as of 5:00 p.m. eastern time on June 6, 2025.
• Every 20 shares of common stock will be automatically converted into one share, without changing the par value per share of $0.00001.
• The reverse stock split will impact all outstanding common shares, shares available under equity incentive plans, and employee stock purchase plans.
• The number of shares issuable upon exercise of stock options, restricted stock units, and warrants will be reduced, with a corresponding increase in their exercise price.
• No fractional shares will be issued; stockholders entitled to fractional shares will receive a cash payment in lieu thereof.
• The Company's common stock is scheduled to begin trading on the Nasdaq Capital Market on a split-adjusted basis on June 9, 2025, under the existing ticker symbol BOLT.
• The new CUSIP number for the common stock following the Reverse Stock Split is 097702203.

Sentiment

Score: 3

Explanation: The announcement of a reverse stock split is generally viewed negatively by the market as it often signals a company's struggle with a low share price and potential delisting concerns, despite being a necessary step for compliance.

Negatives

• A reverse stock split often indicates a company's stock price has fallen significantly, potentially below exchange minimums, signaling underlying challenges or investor concerns.
• While intended to increase share price, reverse splits do not change a company's fundamental value and can sometimes lead to further stock price declines or reduced liquidity.

Risks

• The primary risk implied by a reverse stock split is the company's struggle to maintain its share price above Nasdaq's minimum bid price requirement, risking potential delisting.
• There is a risk that the reverse stock split may not achieve its intended effect of sustainably increasing the stock price or improving market perception.
• The consolidation of shares could lead to reduced trading liquidity.

Future Outlook

The document primarily details a corporate action and does not provide forward-looking statements regarding the company's financial performance or strategic direction beyond the mechanics and effective dates of the reverse stock split.

Industry Context

Reverse stock splits are a common corporate action, particularly for biotechnology companies, when their stock price falls below the minimum bid price required to maintain listing on major exchanges like Nasdaq. This action aims to increase the per-share price to meet listing requirements and potentially attract a broader range of institutional investors, although it does not alter the company's market capitalization or fundamental value.

Comparison to Industry Standards

• The document does not provide specific financial results or project outcomes that can be directly compared to global benchmarks or specific comparable companies within the biotechnology industry.

Corporate Governance

Stakeholder Impact

• Shareholders will own fewer shares, but each share will represent a proportionally larger ownership interest and a higher per-share price, with fractional shares being cashed out.
• Holders of stock options, restricted stock units, and warrants will see their number of underlying shares adjusted and exercise prices increased proportionally.
• Employees participating in equity incentive plans will have their share allocations adjusted.

Next Steps

• The Certificate of Amendment to the Company's Certificate of Incorporation will be filed with the Secretary of State of the State of Delaware.
• The reverse stock split will become effective at 5:00 p.m. eastern time on June 6, 2025.
• The Company's common stock will begin trading on a split-adjusted basis on the Nasdaq Capital Market when the market opens on June 9, 2025.

Key Dates

Recommendation

Keywords

Reverse Stock Split, Common Stock, Nasdaq Capital Market, Corporate Action, Equity Incentive Plans, Stock Options, Warrants, CUSIP, BOLT Biotherapeutics